Drug Trial Radar · NCT07551427
A Clinical Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics of TQ05105 Tablets in Subjects With Intermediate/High-risk Myelofibrosis
Last checked: Nov 20, 2026Latest source record: Jul 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
51
Planned (sponsor's estimate)
Start
Jun 18, 2026
Primary completion
Jun 2028
Study completion Jun 2029
Sponsor
- Lead sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Apr 24, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an open-label, single-arm, multi-center phase II study consisting of two cohorts. Cohort 1 evaluates the pharmacokinetics (PK) of TQ05105 in myelofibrosis participants with normal, mild, or moderate renal impairment to guide dosing. Cohort 2 evaluates the efficacy and safety of TQ05105 in participants with intermediate/high-risk myelofibrosis who are refractory, relapsed, or intolerant to prior Janus kinase (JAK) inhibitor therapy.
Conditions
- Myelofibrosis
Interventions
TQ05105 Tablets (Rovadicitinib Tablets)Drug
TQ05105 is an inhibitor of Janus kinase 1 (JAK1), Janus kinase 2 (JAK2), and Rho-associated coiled-coil containing protein kinase 1 (ROCK1) and 2 (ROCK2).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of subjects with ≥35% reduction in spleen volume from baseline at week 24 (SVR35)Time frame: up to 24 weeks
- Peak concentration (Cmax)Time frame: Pre-dose on Cycle 1 Day 1 and Day 7; and 15, 30, 45 minutes, 1, 2, 3, 4, 6, 8, 12, 24 hours post-dose on Cycle 1 Day 1; and 15, 30, 45 minutes, 1, 2, 3, 4, 6, 8, 12 hours post-dose on Cycle 1 Day 7. (28 days a cycle)
- Time to peak concentration (Tmax)Time frame: Pre-dose on Cycle 1 Day 1 and Day 7; and 15, 30, 45 minutes, 1, 2, 3, 4, 6, 8, 12, 24 hours post-dose on Cycle 1 Day 1; and 15, 30, 45 minutes, 1, 2, 3, 4, 6, 8, 12 hours post-dose on Cycle 1 Day 7. (28 days a cycle)
- Elimination half-life (t1/2)Time frame: Pre-dose on Cycle 1 Day 1 and Day 7; and 15, 30, 45 minutes, 1, 2, 3, 4, 6, 8, 12, 24 hours post-dose on Cycle 1 Day 1; and 15, 30, 45 minutes, 1, 2, 3, 4, 6, 8, 12 hours post-dose on Cycle 1 Day 7. (28 days a cycle)
- Area under the curve from time 0 to last measurable concentration (AUC0-t)Time frame: Pre-dose on Cycle 1 Day 1 and Day 7; and 15, 30, 45 minutes, 1, 2, 3, 4, 6, 8, 12, 24 hours post-dose on Cycle 1 Day 1; and 15, 30, 45 minutes, 1, 2, 3, 4, 6, 8, 12 hours post-dose on Cycle 1 Day 7. (28 days a cycle)
- Area under the curve from time 0 to infinity (AUC0-∞)Time frame: Pre-dose on Cycle 1 Day 1 and Day 7; and 15, 30, 45 minutes, 1, 2, 3, 4, 6, 8, 12, 24 hours post-dose on Cycle 1 Day 1; and 15, 30, 45 minutes, 1, 2, 3, 4, 6, 8, 12 hours post-dose on Cycle 1 Day 7. (28 days a cycle)
- Total clearance (CLt)Time frame: Pre-dose on Cycle 1 Day 1 and Day 7; and 15, 30, 45 minutes, 1, 2, 3, 4, 6, 8, 12, 24 hours post-dose on Cycle 1 Day 1; and 15, 30, 45 minutes, 1, 2, 3, 4, 6, 8, 12 hours post-dose on Cycle 1 Day 7. (28 days a cycle)
- Renal clearance (CLr)Time frame: Pre-dose on Cycle 1 Day 1 and Day 7; and 15, 30, 45 minutes, 1, 2, 3, 4, 6, 8, 12, 24 hours post-dose on Cycle 1 Day 1; and 15, 30, 45 minutes, 1, 2, 3, 4, 6, 8, 12 hours post-dose on Cycle 1 Day 7. (28 days a cycle)
- Apparent volume of distribution (Vd/F)Time frame: Pre-dose on Cycle 1 Day 1 and Day 7; and 15, 30, 45 minutes, 1, 2, 3, 4, 6, 8, 12, 24 hours post-dose on Cycle 1 Day 1; and 15, 30, 45 minutes, 1, 2, 3, 4, 6, 8, 12 hours post-dose on Cycle 1 Day 7. (28 days a cycle)
- Elimination rate constant (λz)Time frame: Pre-dose on Cycle 1 Day 1 and Day 7; and 15, 30, 45 minutes, 1, 2, 3, 4, 6, 8, 12, 24 hours post-dose on Cycle 1 Day 1; and 15, 30, 45 minutes, 1, 2, 3, 4, 6, 8, 12 hours post-dose on Cycle 1 Day 7. (28 days a cycle)
Locations
24 sites in 1 country. Site status is shown where the registry gives one.
The First Affiliated Hospital of University of Science and Technology of China
Hefei, Anhui, China · Recruiting
Fujian Medical University Union Hospital
Fuzhou, Fujian, China · Recruiting
Guangzhou First Municipal People's Hospital
Guangzhou, Guangdong, China · Recruiting
The First Affiliated Hospital of Guangxi Medical University
Nanning, Guangxi, China · Recruiting
Cangzhou People's Hospital rovince
Cangzhou, Hebei, China · Recruiting
Affiliated Hospital of Chengde Medical College
Chengde, Hebei, China · Recruiting
The Second Hospital of Hebei Medical University
Shijiazhuang, Hebei, China · Recruiting
Xingtai People's Hospital
Xingtai, Hebei, China · Recruiting
Henan Cancer Hospital
Zhengzhou, Henan, China · Recruiting
Tongji Hospital affiliated to Tongji Medical College of Huazhong University of Science & Technology
Wuhan, Hubei, China · Recruiting
Union Hospital Tongji College Huazhong University of Science and Technology
Wuhan, Hubei, China · Recruiting
Zhuzhou Central Hospital
Zhuzhou, Hunan, China · Recruiting
Nanjing Drum Tower Hospital
Nanjin, Jiangsu, China · Recruiting
Jiangsu Provincial Hospital of Traditional Chinese Medicine
Nanjing, Jiangsu, China · Recruiting
The First Hospital of Jilin University
Changchun, Jilin, China · Recruiting
Shengjing Hospital Affiliated to China Medical University
Shenyang, Liaoning, China · Recruiting
The First Affiliated Hospital of Air Force Medical University
Xi'an, Shaanxi, China · Recruiting
The First Affiliated Hospital of Xi'an Jiaotong University
Xi'an, Shaanxi, China · Recruiting
Shanghai Sixth People's Hospital
Shanghai, Shanghai Municipality, China · Recruiting
Heping Hospital Affiliated To Changzhi Medical College
Changzhi, Shanxi, China · Recruiting
Sichuan Provincial People's Hospital
Chengdu, Sichuan, China · Recruiting
Chinese Academy of Medical Sciences Hematology Hospital
Tianjin, Tianjin Municipality, China · Recruiting
The First Affiliated Hospital of Xinjiang Medical University
Ürümqi, Xinjiang, China · Recruiting
The First Affiliated Hospital, Zhejiang University School of Medicine
Hangzhou, Zhejiang, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.